The U.S. Food and Drug Administration approved IDVYNSO, a two-drug HIV treatment from Merck (NYSE: MRK), for adults with virologically ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE